Giraffe Bio raises $6.4M to tackle copper shortage with biomolecules

Giraffe Bio has secured a $6.4 million seed round to develop bespoke biomolecules that help miners extract more copper. The funding arrives as AI data centers and electric vehicles drive unprecedented demand for the metal, straining supply chains.

TechCrunch reported the round, which positions the startup at the intersection of biotech and industrial mining. While details on investors and use of funds remain scarce, the deal reflects broader investor appetite for deep-tech solutions addressing resource constraints. Copper prices have climbed in recent years, and some analysts warn of potential shortfalls if extraction rates don’t improve.

Giraffe Bio’s approach—using engineered biomolecules to enhance mineral recovery—echoes recent trends in biotech applied to non-medical sectors. When we covered Mandrake Bio’s $1.9 million pre-seed in October, the focus was on AI-driven gene-editing enzymes; here, the target is industrial, not therapeutic. The shift suggests biotech’s expanding role beyond healthcare, particularly in climate-adjacent markets.

The startup’s timing is notable. The global smartphone market’s 20% Q3 decline, which we reported on 13 October, was partly blamed on memory chip shortages—a reminder of how raw material bottlenecks ripple through hardware industries. Copper’s critical role in wiring, motors, and renewable energy infrastructure makes its supply a potential choke point for AI and EV adoption.

What remains unclear is how Giraffe Bio’s technology scales. Most biomining techniques today target low-grade ores, but the startup hasn’t disclosed its target efficiency gains or pilot partners. For now, the round validates the thesis that biology can optimize industrial processes, even if the path from lab to mine isn’t yet proven.

Sources: techcrunch.com